Eva Barnett
Fortuna: 5 M $ al 30/09/2026
Fortuna: 5 M $ al 30/09/2026
Eva Renee Barnett worked at Eli Lilly & Co. from 2011 to 2012 as Chief Financial Officer-Austria & Switzerland.
From 2015 to 2021, worked at AbleTo, Inc. as Chief Integration Officer.
From 2021 to 2025, worked at Immunovant, Inc. as Chief Financial & Accounting Officer.
Education includes undergraduate studies at DePauw University and an MBA from Harvard Business School.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IMMUNOVANT INC 0,08 % | 30/06/2026 | 157.761 ( 0,08 % ) | 5 M $ | 30/09/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| IMMUNOVANT, INC. | Director Financiero/CFO | 20/04/2025 |
AbleTo, Inc.
AbleTo, Inc. Medical/Nursing ServicesHealth Services Provides online therapy and coaching services for mental health conditions | Director Financiero/CFO | 01/03/2018 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/08/2012 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
AbleTo, Inc.
AbleTo, Inc. Medical/Nursing ServicesHealth Services Provides online therapy and coaching services for mental health conditions | Health Services |
DePauw University
DePauw University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immunovant, Inc.
Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.